Brief: Synlogic Presents Data Demonstrating Reductions In Plasma Phenylalanine Levels In Patients With Phenylketonuria Treated With Synb1618
23/11/2021 24:48
Nov 22 (Reuters) - Synlogic Inc SYBX.O :
* SYNLOGIC PRESENTS DATA DEMONSTRATING REDUCTIONS IN PLASMA
PHENYLALANINE LEVELS IN PATIENTS WITH PHENYLKETONURIA TREATED
WITH SYNB1618
* TREATMENT WITH SYNB1618 WAS GENERALLY WELL TOLERATED, WITH
NO
SERIOUS ADVERSE EVENTS
* DATA DEMONSTRATE ABILITY OF SYNB1618 TO CONSUME
PHENYLALANINE
FROM GI TRACT
Source text for Eikon: ID:nPn6Ml8x1a
Further company coverage: SYBX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary